A Phase 1a/1b, Blinded, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-1740 in Non Cirrhotic, HBV-DNA Negative and Positive Subjects with Chronic HBV Infection.

Trial Profile

A Phase 1a/1b, Blinded, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-1740 in Non Cirrhotic, HBV-DNA Negative and Positive Subjects with Chronic HBV Infection.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs ARB 1740 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 6 Mar 2018 to 6 Nov 2017.
    • 17 Aug 2017 Status changed from recruiting to discontinued.
    • 22 Apr 2017 According to an Arbutus Biopharma media release, results from this trial are expected in 2H 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top